Unruptured Intracranial Aneurysms: Low-Dose Aspirin and Blood Pressure Management

We are studying whether a treatment plan with low-dose aspirin and strict blood pressure control can lower the risk of aneurysm rupture or growth in patients with unruptured intracranial aneurysms. This trial compares this approach to standard care to see if it offers better outcomes.

>2 years >20 visits Confirmation phase (III)No Placebo Standard Medicines OralCardiologyNeurology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Acetylsalicylic Acid

Acetylsalicylic acid is a substance that reduces pain, fever, and inflammation and can help prevent blood clots.

Carbasalate Calcium

Carbasalate calcium is a substance that reduces pain and fever and helps prevent blood clots by stopping platelets from clumping.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

HUS-Yhtymae

Neurosurgery

Helsinki, Finland

Kuopio University Hospital

Neurosurgery

Kuopio, Finland

Oulu University Hospital

Neurosurgery

Oulu, Finland

Sponsor: Heidelberg University

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.